Watanabe Eri, Kometani Satoshi, Tsutsumi Joshi, Takei Tomohide, Tabata Mimiko
Anesthesiology, Yamato Seiwa Hospital, Yamato, JPN.
Cardiology, Yamato Seiwa Hospital, Yamato, JPN.
Cureus. 2024 Aug 15;16(8):e66964. doi: 10.7759/cureus.66964. eCollection 2024 Aug.
Mechanical circulatory support (MCS) using veno-arterial extracorporeal membrane oxygenation (VA-ECMO) is widely implemented as a rescue device in transcatheter aortic valve implantation (TAVI). Although prophylactic VA-ECMO (pECMO) in TAVI is preferable to emergency VA-ECMO (eECMO) in terms of overall survival, there is currently no consensus on the introduction criteria for pECMO. Here, we report four cases of eECMO and pECMO performed in valve-in-valve TAVI (ViV-TAVI) with a small surgical bioprosthesis to consider the validity of the current pECMO indications. In the two cases that were placed on eECMO, a 19 mm and 21 mm Carpentier-Edwards perimount bioprosthesis (CEP), a stented bioprosthetic valve, were sewn. After the transcatheter heart valve (THV) passed through the surgical aortic valve, acute aortic regurgitation developed, thus leading to hemodynamic instability requiring cardiopulmonary resuscitation, and therefore VA-ECMO was introduced. In the two cases using pECMO, 19 mm of CEP were sewn, and the THV was safely placed once MCS had been established. In all four cases, the patients were removed from VA-ECMO in the operating room following ViV-TAVI. The eECMO patients were discharged on postoperative days 12 and 20, while the pECMO patients were discharged on postoperative days 7 and 9, respectively. From our experience and based on the findings of some published reviews, ViV-TAVI with a small surgical bioprosthesis is considered to belong to a high-risk patient group demonstrating hemodynamic instability. The introduction of pECMO for such cases may therefore be an effective option for obtaining a better prognosis.
使用静脉-动脉体外膜肺氧合(VA-ECMO)的机械循环支持(MCS)作为一种抢救设备在经导管主动脉瓣植入术(TAVI)中被广泛应用。尽管就总体生存率而言,TAVI中的预防性VA-ECMO(pECMO)优于紧急VA-ECMO(eECMO),但目前关于pECMO的引入标准尚无共识。在此,我们报告了4例在带小尺寸外科生物瓣的瓣中瓣TAVI(ViV-TAVI)中进行eECMO和pECMO的病例,以探讨当前pECMO适应症的有效性。在接受eECMO的2例病例中,缝合了19毫米和21毫米的Carpentier-Edwards Perimount生物瓣(CEP),一种带支架的生物人工瓣膜。经导管心脏瓣膜(THV)穿过外科主动脉瓣后,发生急性主动脉瓣反流,导致血流动力学不稳定,需要进行心肺复苏,因此引入了VA-ECMO。在使用pECMO的2例病例中,缝合了19毫米的CEP,一旦建立MCS,THV就安全植入。在所有4例病例中,患者在ViV-TAVI术后在手术室撤离VA-ECMO。接受eECMO的患者分别在术后第12天和第20天出院,而接受pECMO的患者分别在术后第7天和第9天出院。根据我们的经验并基于一些已发表综述的研究结果,带小尺寸外科生物瓣的ViV-TAVI被认为属于血流动力学不稳定的高危患者群体。因此,对此类病例引入pECMO可能是获得更好预后的有效选择。